Biotech Values

[genisi]

Agree that the approval path remains murky, I think that removing the peripheral neuropathy isn't enough, carfilzomib needs to show at least 25% ORR in Velcade refractory patients in order to get accelerated approval with this open label single arm phase IIb trial, so far it's 18%.